<DOC>
	<DOC>NCT01783834</DOC>
	<brief_summary>To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer</brief_summary>
	<brief_title>Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Cells pathologically diagnosed as histological or radical surgery or radiation therapy is not possible stage IIIB and stage IV nonsmallcell lung cancer patients second line ECOG 0ï½ž2 Patients with normal liver function and renal function Patients with severe acute infection requiring antibiotic therapy Patients who have received treatment in other areas of cancer within 5 years During pregnancy and lactation patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pemetrexed</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>iressa</keyword>
	<keyword>alimta</keyword>
</DOC>